August 2015

New Product - Hizentra

Hizentra (normal immunoglobulin (human)) contains functionally intact IgG with a broad spectrum of antibodies against infectious agents. Hizentra is indicated in adults and children as replacement therapy in primary immunodeficiency disease (PID) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. Hizentra is contraindicated in hyperprolinaemia type I or II. Hizentra is available as a 20% (20 g/100 mL) solution for infusion in a 5 mL, 10 mL, 20 mL and 50 mL single use vial.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au